Erratum: AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis (EMBO Reports (2012) 13 (554-560) DOI: 10.1038/embor.2012.53);AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis

EMBO Reports

Volumn 13, Issue 6, 2012, Pages 554-560

  Ji, Haitao ^a   Ding, Zhiyong ^a   Hawke, David ^a   Xing, Dongming ^b   Jiang, Bing Hua ^c   Mills, Gordon B ^a   Lu, Zhimin ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TSINGHUA UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

AKT; apoptosis; MDM2; Niban; nucleophosmin; p53

Indexed keywords

NIBAN PROTEIN; NUCLEOPHOSMIN; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROTECTION; CELL STRESS; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; ULTRAVIOLET IRRADIATION;

EID: 84861914228     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201439354     Document Type: Erratum

References (38)

1. Majima S, Kajino K, Fukuda T, Otsuka F, Hino O (2000) A novel gene 'Niban' upregulated in renal carcinogenesis: cloning by the cDNA-amplified fragment length polymorphism approach. Jpn J Cancer Res 91: 869-874
2. Matsumoto F, Fujii H, Abe M, Kajino K, Kobayashi T, Matsumoto T, Ikeda K, Hino O (2006) A novel tumor marker, Niban, is expressed in subsets of thyroid tumors and Hashimoto's thyroiditis. Hum Pathol 37: 1592-1600 (Pubitemid 44792227)
3. Ito S, Fujii H, Matsumoto T, Abe M, Ikeda K, Hino O (2010) Frequent expression of Niban in head and neck squamous cell carcinoma and squamous dysplasia. Head Neck 32: 96-103
4. Kannangai R, Diehl AM, Sicklick J, Rojkind M, Thomas D, Torbenson M (2005) Hepatic angiomyolipoma and hepatic stellate cells share a similar gene expression profile. Hum Pathol 36: 341-347 (Pubitemid 40591803)
5. Adachi H et al (2004) Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis. Oncogene 23: 3495-3500 (Pubitemid 38669840)
6. Sun GD, Kobayashi T, Abe M, Tada N, Adachi H, Shiota A, Totsuka Y, Hino O (2007) The endoplasmic reticulum stress-inducible protein Niban regulates eIF2a and S6K1/4E-BP1 phosphorylation. Biochem Biophys Res Commun 360: 181-187 (Pubitemid 46990340)
7. Vousden KH, Prives C (2009) Blinded by the Light: the Growing Complexity of p53. Cell 137: 413-431
8. Whibley C, Pharoah PD, Hollstein M (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107
9. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G. The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol 12: 259-265
10. Junttila MR, Evan GI (2009) p53-a Jack of all trades but master of none. Nat Rev Cancer 9: 821-829
11. Chene P (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109
12. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137: 609-622
13. Iwakuma T, Lozano G (2003) MDM2, an introduction. Mol Cancer Res 1: 993-1000 (Pubitemid 38044974)
14. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4: 529-533 (Pubitemid 34752440)
15. Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, Laiho M (2004) Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5: 465-475 (Pubitemid 38610248)
16. Pawson T, Scott JD (2005) Protein phosphorylation in signaling-50 years and counting. Trends Biochem Sci 30: 286-290 (Pubitemid 40799044)
17. Lu Z, Hunter T (2009) Degradation of activated protein kinases by ubiquitination. Annu Rev Biochem 78: 435-475
18. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R (2003) Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9: 1145-1154 (Pubitemid 36323724)
19. Lopez CA, Feng FY, Herman JM, Nyati MK, Lawrence TS, Ljungman M (2007) Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int J Radiat Oncol Biol Phys 69: 214-220 (Pubitemid 47247526)
20. Obenauer JC, Cantley LC, Yaffe MB (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31: 3635-3641 (Pubitemid 37442212)
21. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P (1996) Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett 399: 333-338 (Pubitemid 26426877)
22. Fang D et al (2007) Phosphorylation of b-catenin by AKT promotes b-catenin transcriptional activity. J Biol Chem 282: 11221-11229 (Pubitemid 47100795)
23. Hoyal CR, Gutierrez A, Young BM, Catz SD, Lin JH, Tsichlis PN & Babior BM (2003) Modulation of p47PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc Natl Acad Sci U S A 100: 5130-5135 (Pubitemid 36542670)
24. Hirai H et al (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9: 1956-1967
25. Wan YS, Wang ZQ, Shao Y, Voorhees JJ, Fisher GJ (2001) Ultraviolet irradiation activates PI3-kinase/AKT survival pathway via EGF receptors in human skin in vivo. Int J Oncol 18: 461-466
26. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S (2005) Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci USA 102: 192-197 (Pubitemid 40094451)
27. Bertwistle D, Sugimoto M, Sherr CJ (2004) Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 24: 985-996 (Pubitemid 38112164)
28. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, Pandolfi PP (2005) Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437: 147-153 (Pubitemid 41613442)
29. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004
30. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510
31. West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resistance Updates 5: 234-248 (Pubitemid 36132805)
32. Parsons CM, Muilenburg D, Bowles TL, Virudachalam S, Bold RJ. The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res 30: 3279-3289
33. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277: 21843-21850 (Pubitemid 34952337)
34. Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598-11603 (Pubitemid 32928774)
35. Van der Vorst S, Dekairelle AF, Weynand B, Hamoir M, Gala JL (2011) Assessment of p53 functional activity in tumor cells and histologically normal mucosa from patients with head and neck squamous cell carcinoma. Head Neck (Epub ahead of print, doi:10.1002/hed.21960)
36. Bussink J, van der Kogel AJ, Kaanders JH (2008) Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9: 288-296 (Pubitemid 351722948)
37. Xia Y, Wang J, Liu TJ, Yung WK, Hunter T, Lu Z (2007) c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol Cell 25: 219-232 (Pubitemid 46109614)
38. Ji H et al (2009) EGF-induced ERK activation promotes CK2-mediated disassociation of α-catenin from β-catenin and transactivation of β-catenin. Mol Cell 36: 547-559